The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
The 5' flanking region of the C3(1) component of the rat prostate steroid binding protein (PSBP) has been used to successfully target the expression of the SV40 large T-antigen (Tag) to the epithelium of both the mammary and prostate glands resulting in models of mammary and prostate cancers which histologically resemble the human diseases. Atypia of the mammary ductal epithelium develops at about 8 weeks of age, progressing to mammary intraepithelial neoplasia (resembling human ductal carcinoma in situ [DCIS]) at about 12 weeks of age with the development of invasive carcinomas at about 16 weeks of age in 100% of female mice. The carcinomas share features to what has been classified in human breast cancer as infiltrating ductal carcinomas. All FVB/N female mice carrying the transgene develop mammary cancer with about a 15% incidence of lung metastases. Approximately 10% of older male mice develop anaplastic mammary carcinomas. Unlike many other transgenic models in which hormones and pregnancy are used to induce a mammary phenotype, C3(1)/Tag mice develop mammary tumors in the mammary epithelium of virgin animals without hormone supplementation or pregnancy. Although mammary tumor development appears hormone-responsive at early stages, invasive carcinomas are hormone-independent, which corresponds to the loss of estrogen receptor-alpha expression during tumor progression. Molecular and biologic factors related to mammary tumor progression can be studied in this model since lesions evolve over a predictable time course. Genomic alterations have been identified during tumor progression, including an amplification of the distal portion of chromosome 6 containing ki-ras and loss of heterozygosity (LOH) in other chromosomal regions. We have demonstrated that stage specific alterations in the expression of genes which are critical regulators of the cell cycle and apoptosis are functionally important in vivo. C3(1)/Tag mice appear useful for testing particular therapies since growth of the mammary tumors can be reduced using chemopreventive agents, cytokines, and an anti-angiogenesis agent.
Green
J E
JE
Transgenic Oncogenesis Group, Laboratory of Cell Regulation and Carcinogenesis, Building 41, Room C629, NCI, Bethesda, Maryland, MD 20892, USA.
Shibata
M A
MA
Yoshidome
K
K
Liu
M L
ML
Jorcyk
C
C
Anver
M R
MR
Wigginton
J
J
Wiltrout
R
R
Shibata
E
E
Kaczmarczyk
S
S
Wang
W
W
Liu
Z Y
ZY
Calvo
A
A
Couldrey
C
C
D000727:Androgen-Binding Protein / Q000235:genetics* / Q000378:metabolism; D000818:Animals; D000952:Antigens, Polyomavirus Transforming / Q000235:genetics*; D017209:Apoptosis; D018270:Carcinoma, Ductal, Breast / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D002453:Cell Cycle / Q000235:genetics; D004195:Disease Models, Animal; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D007167:Immunotherapy; D008325:Mammary Neoplasms, Experimental / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D051379:Mice; D008822:Mice, Transgenic; D049488:Phosphatidylethanolamine Binding Protein; D011247:Pregnancy; D060789:Prostatein; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2; D051381:Rats; D060765:Secretoglobins; D014598:Uteroglobin; D051028:bcl-2-Associated X Protein; D060788:Mammaglobin B
D000727:Androgen-Binding Protein; D000952:Antigens, Polyomavirus Transforming; D049488:Phosphatidylethanolamine Binding Protein; D060789:Prostatein; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D060765:Secretoglobins; D014598:Uteroglobin; D051028:bcl-2-Associated X Protein; C511482:PEBP1 protein, human; C511484:Scgb1d2 protein, rat; C511483:Scgb1d4 protein, rat; C556468:Scgb2a1 protein, rat; D060788:Mammaglobin B